Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Immunology

Serology testing for COVID-19 is the way forward, but we could face a long wait

While news of imminent serology testing is incredibly encouraging, we must be pragmatic about how quickly it can be made available to the general public.

Open access article

The Royal Pharmaceutical Society has made this article free to access in order to help healthcare professionals stay informed about an issue of national importance.

To learn more about coronavirus, please visit: https://www.rpharms.com/resources/pharmacy-guides/wuhan-novel-coronavirus

Serology testing for COVID 19 is the way forward but we could face a long wait

Source: Shutterstock.com

Finger prick tests have not yet been validated for use by Public Health England

The news that Abbott Laboratories has launched a new serology test to detect COVID-19 infection, and that Roche will do the same in May 2020, is very welcome. It is heartening that these large and experienced diagnostic companies have managed to rapidly develop a so-called “antibody test”.

There has been much media attention on the current UK testing regimen for COVID-19 infection — particularly regarding the government’s target of 100,000 tests per day by the end of April 2020. However, commentators have concentrated less on testing for those who may have had the infection; with the immunity this could confer, serology testing could be the more powerful test.

We do not know how many people in the UK have had this coronavirus. Although a large UK study was launched in April 2020 to investigate this, with additional testing still ongoing, it is a blind spot that prevents us from getting back to something that resembles normal life.

The official figures presented at the UK government’s daily briefings are based solely on cases admitted to hospital and do not include those in the community who have been infected. An additional complication is that there may be a very large number of people who have been infected but had no symptoms — estimates vary from 8% to 80%.

The restrictions that are currently in place to encourage social distancing exist to reduce the spread of infection, but many people — including NHS key workers — could be safe to go back to work if they could prove they had immunity to COVID-19.

The launch of any test is only the first step — they would need to be subjected to rigorous and independent validation before use on the general public

This testing could also open the door to the use of antibody-rich convalescent plasma from those who have survived the infection as a treatment for those in intensive care. However, the launch of any test is only the first step — they would need to be subjected to rigorous and independent validation before use on the general public. 

It is easy to show that someone has antibodies to one or more of the proteins on the viral coat of COVID-19, but it is more difficult to show that those proteins are specific to COVID-19 and were not produced as the result of another coronavirus — a common cause of coughs and colds. Additionally, any test must measure the amount of antibodies capable of ‘neutralising’ an infection, in order to provide a reliable measure of immunity.

Both of these will be crucial areas to establish before any serological test can be rolled out.

We do not know how long immunity to COVID-19 infection lasts, although the signs seem good from other coronaviruses such as SARS-CoV-1, which confers immunity 17 years after infection. However, viruses are constantly evolving; an accurate test could be rendered obsolete if SARS-CoV-2 mutates in a way that causes the proteins on its coat to change. The false assurance of a failed test could be more dangerous than nothing at all.

Indeed, an object lesson is that the millions of fingerprick tests, mainly from Chinese manufacturers, bought by the UK government that have not been validated for use by Public Health England, despite officials raising hopes they could be available from Amazon and Boots in the near future.

There is a lot riding on the protein targets that diagnostic companies choose and it is not clear yet whether any of the tests developed so far will be able to be scaled up quickly enough to meet the demands of policy makers. The serology tests from Abbott Laboratories and Roche appear to be laboratory based, which is very different to a test kit being sent out in the post. 

Aidan Fowler, deputy chief medical officer for England (and who is currently recovering from COVID-19) told an NHS England and NHS Improvement webinar on 22 April 2020 that the antibody test technology is “not where we would want it at the moment”, but that the situation is “rapidly changing”.

This is an unprecedented challenge. It will require co-operation and an enormous amount of ingenuity to deliver successfully before these tests are seen on the shelves of community pharmacies in the UK. But, if scientists can get this right, the prize would be enormous.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20207918

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Workplace Drug Testing

    Workplace Drug Testing

    Explains drug testing regulatory frameworks and all aspects of drug analysis. Case studies of successful programmes are included.

    £81.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.